Astrazeneca gets a win for its SGLT2 in heart failure irrespective of diabetes status, but Lilly and Boehringer’s Jardiance isn’t far behind.
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Citing study failure, Sanofi terminates its tie-up with Lexicon covering Zynquista; not so fast, says Lexicon, and claims breach of contract.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
Pfizer launches an $11.4bn bid for the prolific originator of small molecules, and predicts blockbuster sales in colorectal cancer to help justify the price.